Patents by Inventor Juan Pablo Cerliani

Juan Pablo Cerliani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment
    Patent number: 11020478
    Abstract: A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: June 1, 2021
    Assignees: Inis Biotech LLC, Consejo Nacional de Investigaciones Científicas y Técnicas, Funadción Sales
    Inventors: Gabriel Adrian Rabinovich, Diego Omar Croci Russo, Juan Pablo Cerliani, Mariana Salatino, Pablo Francisco Hockl, Juan Manuel Pérez Sáez
  • Methods for Modulating Angiogenesis of Cancers Refractory to Anti-VEGF Treatment
    Publication number: 20200016266
    Abstract: A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.
    Type: Application
    Filed: May 20, 2019
    Publication date: January 16, 2020
    Inventors: Gabriel Adrian Rabinovich, Diego Omar Croci Russo, Juan Pablo Cerliani, Mariana Salatino, Pablo Francisco Hockl, Juan Manuel Pérez Sáez
  • Therapeutic modulation of skin immune system with Gal-7
    Patent number: 10456447
    Abstract: This invention provides methods of modulating immune responses in the skin. The invention further provides methods of treatment for psoriasis, epidermal and dermal inflammation, and associated dermal immunity conditions by administering to an individual patient in need an effective amount of Gal-7, functional fragments of Gal-7, or agonists of Gal-7.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: October 29, 2019
    Assignee: Consejo Nacional de Investigacions Cientificas y Técnicas
    Inventors: Gabriel A. Rabinovich, Juan Pablo Cerliani, Nicolás Alejandro Pinto
  • Methods for modulating angiogenesis of cancers refractory to anti-VEGF treatment
    Patent number: 10294295
    Abstract: A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: May 21, 2019
    Assignees: INIS Biotech LLC, Consejo Nacional de Investigaciones Cientificas Y Tecnicas, Fundacion Sales
    Inventors: Gabriel Adrian Rabinovich, Diego Omar Croci Russo, Juan Pablo Cerliani, Mariana Salatino
  • THERAPEUTIC MODULATION OF SKIN IMMUNE SYSTEM WITH GAL-7
    Publication number: 20180110830
    Abstract: This invention provides methods of modulating immune responses in the skin. The invention further provides methods of treatment for psoriasis, epidermal and dermal inflammation, and associated dermal immunity conditions by administering to an individual patient in need an effective amount of Gal-7, functional fragments of Gal-7, or agonists of Gal-7.
    Type: Application
    Filed: October 5, 2017
    Publication date: April 26, 2018
    Inventors: Gabriel A. Rabinovich, Juan Pablo Cerliani, Nicolás Alejandro Pinto
  • Methods for Modulating Angiogenesis of Cancers Refractory to Anti-VEGF Treatment
    Publication number: 20170037120
    Abstract: A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.
    Type: Application
    Filed: November 26, 2014
    Publication date: February 9, 2017
    Inventors: Gabriel Adrian Rabinovich, Diego Omar Croci Russo, Juan Pablo Cerliani, Mariana Salatino